| Autor: |
Weidner, J. W., Nortier, F. M., Bach, H. T., John, K. D., Couture, A., Ullmann, J. L., Fassbender, M. E., Goff, G. S., Taylor, W., Valdez, F., Wolfsberg, L. E., Cisneros, M., Dry, D., Gallegos, M., Gritzo, R., Bitteker, L. J., Wender, S., Baty, R. S. |
| Předmět: |
|
| Zdroj: |
AIP Conference Proceedings; 6/1/2011, Vol. 1336 Issue 1, p423-425, 3p, 1 Black and White Photograph, 1 Diagram |
| Abstrakt: |
225Ac has tremendous potential for the treatment of metastatic cancer due to the four alpha-particles emitted during its decay to stable 209Bi. Additionally, it is one of the few alpha-emitters being considered for clinical trials. The anticipated 225Ac demand for these trials is expected to far exceed the annual worldwide supply of approximately 1,000 mCi/yr. Consequently, the DOE Office of Science has funded investigations into accelerator-based production of 225Ac. Existing 232Th(p,x)225Ac cross section data indicate that up to 480 mCi/day of 225Ac could be created by bombarding a thick target of natural thorium with 100 MeV protons at the Los Alamos Isotope Production Facility. To verify these predictions, experiments are underway at the Los Alamos Neutron Science Center to measure the 232Th(p,x)225Ac production cross sections for protons in the energy range 40-200 MeV, and at 800 MeV. For 800 MeV protons, preliminary results indicate that the 225Ac production cross section is 12.4±0.6 mb and the 225Ra production cross section is 3.2±0.2 mb. Moreover, preliminary results suggest that the 227Ac production cross section is 16±1 mb. Experiments to measure these same cross sections at proton energies below 200 MeV are planned for the last half of calendar year 2010. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
